Theresa Alenghat Granted AGA-CCFA-Janssen Award For IBD Epigenetics Research

Theresa Alenghat Granted AGA-CCFA-Janssen Award For IBD Epigenetics Research
The inaugural 2015 AGA-CCFA-Janssen Research Award in Inflammatory Bowel Disease (IBD) Epigenetics Research was recently awarded by the American Gastroenterological Association (AGA), in partnership with the Crohn's & Colitis Foundation of America (CCFA) and Janssen Biotech, Inc. (Janssen). The association announced that Theresa Alenghat, VMD, PhD will be granted $100,000 per year for three years to study the role of epigenetics in the development of IBD. The award winning investigator works at the Cincinnati Children's Hospital Medical Center, OH and her research is the first to receive this recognition and financial support. Epigenetics refers to DNA and DNA-related proteins alterations that result from patient and environmental factors, a field that is thought to contribute to the development of novel reversible and targeted treatments for patients who suffer from ulcerative colitis and Crohn's disease, the two most common forms of IBD. "With this grant, I will have the resources to conduct both basic and translational research initiatives to test how bacteria trigger changes in the epigenome during the development of IBD," said in a press release Dr. Alenghat, who serves as assistant professor in the division of immunobiology at Cincinnati Children's Hospital Medical Center. "These novel insights may guide the development of more effective and tailored therapeutic approaches for managing IBD." Epigenetics is a field of increasing interest in research for not only IBD but also numerous other diseases. Epigenomic alterations are able to regulate gene expression when triggered by environmental factors, but they don't alter the genetic sequence. Therefore, Dr. Alenghat's research will be focused on dysregulation of epigenomic modifications, whi
Subscribe or to access all post and page content.